MSON - ミソニックス (MISONIX Inc.)

MSONのニュース

   Misonix to Report Fiscal 2021 Second Quarter Financial Results and Host Conference Call and Webcast on February 4 - Stocks News Feed  2021/01/21 15:30:00 Stocks News Feed
FARMINGDALE, N.Y., Jan. 21, 2021 (GLOBE NEWSWIRE) — Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 second quarter financial results after the market closes on Thursday, February 4, 2021. The Company will host a conference… Read More »Misonix to Report Fiscal 2021 Second Quarter Financial Results and Host Conference Call and Webcast on February 4
   Tumor Ablation Market 2020 Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Boston Scientific, Medtronic, Misonix, Smith & Nephew, Abbott, BVM Medical  2020/10/14 15:09:54 OpenPR
The winning Tumor Ablation Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players
   Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound  2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
   Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2020 Results - Earnings Call Transcript  2020/09/04 02:05:05 Seeking Alpha
Start Time: 16:30 End Time: 17:06 Misonix, Inc. (NASDAQ:MSON) Q4 2020 Earnings Conference Call September 03, 2020, 16:30 PM ET Company Participants Stavros Vizirgianakis - CEO Joseph Dwyer - CFO Norberto Aja - IR Conference Call Participants Kyle Rose - Canaccord Genuity Ryan Zimmerman - BTIG Alex Nowak - Craig-Hallum Capital Group Presentation Operator Good day, and welcome to the Misonix Fourth Quarter Fiscal Year 2020 Earnings Call.
   Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson  2020/03/24 11:01:00 Benzinga Feeds
DUBLIN , March 24, 2020 /PRNewswire/ -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering. The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic. As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung.
   Tumor Ablation Market 2020 Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Boston Scientific, Medtronic, Misonix, Smith & Nephew, Abbott, BVM Medical  2020/10/14 15:09:54 OpenPR
The winning Tumor Ablation Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players
   Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound  2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
   Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2020 Results - Earnings Call Transcript  2020/09/04 02:05:05 Seeking Alpha
Start Time: 16:30 End Time: 17:06 Misonix, Inc. (NASDAQ:MSON) Q4 2020 Earnings Conference Call September 03, 2020, 16:30 PM ET Company Participants Stavros Vizirgianakis - CEO Joseph Dwyer - CFO Norberto Aja - IR Conference Call Participants Kyle Rose - Canaccord Genuity Ryan Zimmerman - BTIG Alex Nowak - Craig-Hallum Capital Group Presentation Operator Good day, and welcome to the Misonix Fourth Quarter Fiscal Year 2020 Earnings Call.
   Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson  2020/03/24 11:01:00 Benzinga Feeds
DUBLIN , March 24, 2020 /PRNewswire/ -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering. The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic. As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung.
   The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment  2020/03/11 12:03:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
   Tumor Ablation Market 2020 Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Boston Scientific, Medtronic, Misonix, Smith & Nephew, Abbott, BVM Medical  2020/10/14 15:09:54 OpenPR
The winning Tumor Ablation Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players
   Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound  2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
   Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2020 Results - Earnings Call Transcript  2020/09/04 02:05:05 Seeking Alpha
Start Time: 16:30 End Time: 17:06 Misonix, Inc. (NASDAQ:MSON) Q4 2020 Earnings Conference Call September 03, 2020, 16:30 PM ET Company Participants Stavros Vizirgianakis - CEO Joseph Dwyer - CFO Norberto Aja - IR Conference Call Participants Kyle Rose - Canaccord Genuity Ryan Zimmerman - BTIG Alex Nowak - Craig-Hallum Capital Group Presentation Operator Good day, and welcome to the Misonix Fourth Quarter Fiscal Year 2020 Earnings Call.
   Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson  2020/03/24 11:01:00 Benzinga Feeds
DUBLIN , March 24, 2020 /PRNewswire/ -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering. The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period. The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that is expected to further assist in facilitating the therapeutic. As the trend towards decreased invasiveness of medical procedures persists, image-guided percutaneous ablation has started supplanting surgery for local control of small tumors in the liver, kidney, and lung.
   The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment  2020/03/11 12:03:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.

calendar